Skip to main content
Midas Edge

Co-Diagnostics Inc

For the period ended Mar 31, 2024. Filed May 9, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 9, 2024

CODX$0.29-9.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

Convertible Preferred Stock · Common Stock · Treasury · Additional Paid-in · Accumulated Other Comprehensive · Accumulated Earnings · Total Stockholders’
Shares · Amount · Shares · Amount · Stock · Capital · Income · (Deficit) · Equity
Balance as of December 31, 2023--36,108,34636,108(15,575,795)96,808,436146,7004,598,16686,013,615
Stock-based compensation--18,75019-1,571,215--1,571,234
Other comprehensive income, net of tax------79,855-79,855
Net loss-------(9,312,043)(9,312,043)
Balance as of March 31, 2024-$-36,127,096$36,127$(15,575,795)$98,379,651$226,555$(4,713,877)$78,352,661
Convertible Preferred Stock · Common Stock · Treasury · Additional Paid-in · Accumulated Other Comprehensive · Accumulated Earnings · Total Stockholders’
Shares · Amount · Shares · Amount · Stock · Capital · Income · (Deficit) · Equity
Balance as of December 31, 2022-$-34,754,265$34,754$(14,211,866)$88,472,935$293,140$39,931,031$114,519,994
Stock-based compensation--68,75069-2,168,673--2,168,742
Repurchases of common stock----(482,196)---(482,196)
Other comprehensive income, net of tax------178,621-178,621
Net loss-------(5,755,391)(5,755,391)
Balance as of March 31, 2023-$-34,823,015$34,823$(14,694,062)$90,641,608$471,761$34,175,640$110,629,770
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.